Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $27000.0.

  • Ovid Therapeutics' Change in Accured Expenses rose 10504.67% to $27000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 44844.44%. This contributed to the annual value of -$537000.0 for FY2024, which is 12657.1% down from last year.
  • Ovid Therapeutics' Change in Accured Expenses amounted to $27000.0 in Q3 2025, which was up 10504.67% from -$3.1 million recorded in Q2 2025.
  • Ovid Therapeutics' 5-year Change in Accured Expenses high stood at $4.1 million for Q2 2024, and its period low was -$3.4 million during Q3 2021.
  • In the last 5 years, Ovid Therapeutics' Change in Accured Expenses had a median value of -$1000.0 in 2025 and averaged -$482316.6.
  • Data for Ovid Therapeutics' Change in Accured Expenses shows a peak YoY increase of 20178.04% (in 2024) and a maximum YoY decrease of 62277.23% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Ovid Therapeutics' Change in Accured Expenses stood at $748263.0 in 2021, then plummeted by 259.64% to -$1.2 million in 2022, then skyrocketed by 125.36% to $303000.0 in 2023, then plummeted by 622.77% to -$1.6 million in 2024, then skyrocketed by 101.7% to $27000.0 in 2025.
  • Its Change in Accured Expenses was $27000.0 in Q3 2025, compared to -$3.1 million in Q2 2025 and -$1000.0 in Q1 2025.